TDOC

Teladoc Health Inc

Add to Watchlist

Advanced Chart

8.190

+0.24(3.019%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

8.240

Open

7.860

VWAP

8.05

Vol

5.66M

Mkt Cap

1.45B

Low

7.770

Amount

45.62M

EV/EBITDA(TTM)

9.74

Total Shares

169.59M

1.72B

EV/OCF(TTM)

5.66

P/S(TTM)

0.54

Teladoc Health, Inc. provides virtual healthcare services. Its segments include Teladoc Health Integrated Care (Integrated Care) and BetterHelp. Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. Services in this segment are distributed on a B2B basis. BetterHelp segment includes direct-to-consumer mental health platform. The online counseling and therapy services are provided via its network of over 35,000 licensed clinicians leveraging its platform for Web, mobile app, phone, and text-based interactions. Its Teladoc Health family of brands, including Teladoc and BetterHelp, deliver access to advice and resolution for an array of healthcare needs. Its Telecare brand is a tech-enabled provider of specialist and allied health care via virtual delivery.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

631.86M

+0.4%

-0.320

+46.25%

634.31M

-0.96%

-0.243

-0.72%

625.92M

-2.28%

-0.307

+79.87%

Estimates Revision

The market is revising Upward the revenue expectations for Teladoc Health, Inc. (TDOC) for FY2025, with the revenue forecasts being adjusted by 0.22% over the past three months. During the same period, the stock price has changed by 3.80%.

Revenue Estimates for FY2025

Revise Upward

+0.22%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+9.55%

In Past 3 Month

Stock Price

Go Up

+3.80%

In Past 3 Month

13 Analyst Rating

11.72% Upside

Wall Street analysts forecast TDOC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TDOC is 9.15 USD with a low forecast of 7.50 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

10 Hold

0 Sell

Hold

11.72% Upside

Current: 8.190

Low

7.50

Averages

9.15

High

12.00

11.72% Upside

Current: 8.190

Low

7.50

Averages

9.15

High

12.00

Cantor Fitzgerald

Sarah James

Overweight

downgrade

$12 -> $10

2025-07-30

Reason

Cantor Fitzgerald

Sarah James

Price Target

$12 -> $10

2025-07-30

downgrade

Overweight

Reason

Cantor Fitzgerald analyst Sarah James lowered the firm's price target on Teladoc to $10 from $12 and keeps an Overweight rating on the shares. Teladoc's long-term growth in BetterHelp is heavily levered towards insurance coverage, but there are more pathways to sustainable growth in Integrated Care, the analyst tells investors in a research note. The firm believes more proof is needed on a return to revenue growth in BetterHelp before the multiple lifts.

Mizuho

Steven Valiquette

Neutral

initiated

$10

2025-07-25

Reason

Mizuho

Steven Valiquette

Price Target

$10

2025-07-25

initiated

Neutral

Reason

Mizuho analyst Steven Valiquette initiated coverage of Teladoc with a Neutral rating and $10 price target. The firm is encouraged by Teladoc's growth in its Integrated Care segment but is concerned about the potential pace of BetterHelp attrition over the near term. The company's customer acquisition costs remain elevated, and consumer sentiment remains well below historical averages in 2025, the analyst tells investors in a research note.

BofA

Neutral

maintain

2025-07-03

Reason

BofA

Price Target

2025-07-03

maintain

Neutral

Reason

BofA raised the firm's price target on Teladoc to $8.75 from $7 and keeps a Neutral rating on the shares. Teladoc's recent acquisitions of Catapult and Uplift provide optionality to drive higher revenue per member, but it will take both time and execution to improve the revenue growth outlook, the analyst tells investors in a research note. BofA remains cautious on full-year guidance and momentum into 2026 but views recent acquisitions as potential catalysts for growth.

BofA

Neutral

downgrade

$8 -> $7

2025-05-28

Reason

BofA

Price Target

$8 -> $7

2025-05-28

downgrade

Neutral

Reason

BofA lowered the firm's price target on Teladoc to $7 from $8 and keeps a Neutral rating on the shares. In April, global BetterHelp MAUs declined 6.1% year-over-year, further decelerating from low single-digit declines in the prior month, according to the analyst, who cites lower peer multiples for the firm's lowered price target. The firm remains cautious on the near-term outlook, but could see investments for future growth driving greater patient engagement over time, the analyst added.

Truist

Hold

downgrade

$10 -> $9

2025-05-27

Reason

Truist

Price Target

$10 -> $9

2025-05-27

downgrade

Hold

Reason

Truist lowered the firm's price target on Teladoc to $9 from $10 and keeps a Hold rating on the shares. The firm is updating its model after the company's Q1 results with expectations of slightly lower 2026 EBITDA, the analyst tells investors in a research note. Longer term, Truist notes that with about 90M U.S. members having access to its offerings, Teladoc has the scale and depth to take advantage of various growth opportunities across the healthcare continuum.

Citi

Neutral

downgrade

$11

2025-04-25

Reason

Citi

Price Target

$11

2025-04-25

downgrade

Neutral

Reason

Citi lowered the firm's price target on Teladoc to $8.75 from $11 and keeps a Neutral rating on the shares. The firm also added an "upside 30-day short-term view" on the shares. It is likely that BetterHelp beats on sales this quarter, the analyst tells investors in a research note. Citi does not expect any change to Teladoc's guidance and, given consumer spending concerns, it thinks management will strike a cautious tone. However, given bearish sentiment, "this should be good enough" for a positive stock price reaction, contends the firm.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Teladoc Health Inc (TDOC.N) is -7.26, compared to its 5-year average forward P/E of -44.92. For a more detailed relative valuation and DCF analysis to assess Teladoc Health Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-44.92

Current PE

-7.26

Overvalued PE

22.24

Undervalued PE

-112.09

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

35.67

Current EV/EBITDA

6.27

Overvalued EV/EBITDA

75.56

Undervalued EV/EBITDA

-4.21

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4.21

Current PS

0.56

Overvalued PS

9.28

Undervalued PS

-0.86